|
| Potent Mechanism-Based Inactivation of CYP3A4 by CHIR99021: Metabolic Fate and Drug Interaction Liability of a Widely Used GSK-3β Inhibitor |
| DR. RYU, Changseon |
| Kist Europe Forschungsgesellschaft Mbh |
| Dr. Ryu is a Senior Researcher at KIST Europe in Saarbrücken, Germany. He studied Pharmacy as an undergraduate and earned his Master's and PhD in biological pharmacy (toxicology/drug metabolism) at Chungnam National University, followed by postdoctoral training at IKP-Stuttgart. His research focuses on metabolic disruption—including MASLD and endocrine disruption, thyroid hormone, and other metabolic dysfunction—studied through non-targeted and targeted metabolomics/lipidomics by high-resolution mass spectrometry (HRMS) and new approach methodologies (NAMs). His work spans drug metabolism and drug-induced toxicity, reactive metabolite profiling, and the regulation of drug-metabolizing enzymes (cytochrome P450, UGT, GST), using non-targeted analysis (NTA) to capture endogenous metabolite/lipid perturbations and characterize xenobiotic metabolites. |
|
|